Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Parallel Review Could Deter NCD, Medicare Exec Says; Provenge A Case In Point?

Executive Summary

Overlapping FDA product approval and Medicare coverage reviews could help biopharmaceutical firms avoid a later Medicare national coverage determination for a new therapy, CMS Coverage and Analysis Group Director Louis Jacques suggested during a webinar sponsored by Avalere Health Sept. 30.

You may also be interested in...



FDA/CMS Parallel Review: Firms Lack Incentive To Participate, Lawyers Say

As drug industry advisors scrutinize FDA’s and CMS’ recent proposal to institute voluntary parallel reviews of new medical products, some are seeing little reason for manufacturers to subject their products to parallel review.

FDA/CMS Parallel Review: Firms Lack Incentive To Participate, Lawyers Say

As drug industry advisors scrutinize FDA’s and CMS’ recent proposal to institute voluntary parallel reviews of new medical products, some are seeing little reason for manufacturers to subject their products to parallel review.

Provenge Off-Label Use Is Key CMS Concern In NCA, Dendreon Says

In its ongoing national coverage analysis of Dendreon's Provenge (sipuleucel-T), the Centers for Medicare and Medicaid Services is taking a close look at Medicare coverage for off-label use of the novel prostate cancer vaccine, according to the company

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel